Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to CR7270ApriorityCriticalpatent/CR7270A/en
Publication of CR7270ApublicationCriticalpatent/CR7270A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
La presente invencion se refiere a una formulacion de inhalacion que comprende un compuesto seleccionado entre una clase particular de 5, 6- dihidro-9h-pirazolo (3,4-c)- 1, 2, 4- triazolo (4, 3-a) piridinas, que es capaz de liberar el compuesto en forma de particulas solidas finas en el pulmon, y al uso de tal formulacion en el tratamiento de ciertas enfermedades tales como las enfermedades respiratorias.The present invention relates to an inhalation formulation comprising a compound selected from a particular class of 5, 6- dihydro-9h-pyrazolo (3,4-c) -1, 2, 4- triazolo (4, 3-a ) pyridines, which is capable of releasing the compound in the form of fine solid particles in the lung, and to the use of such a formulation in the treatment of certain diseases such as respiratory diseases.
CR7270A2004-03-032004-03-03
USE OF COMPOUNDS IN A DRY POWDER INHALER
CR7270A
(en)
Compounds derived from condensed pyrimidine, pi3-kinase inhibitors; processes to prepare the compounds; pharmaceutical composition that includes them; use of the compounds in the preparation of medicaments; process to prepare the pharmaceutical composition; and kit that includes the pharmaceutical composition
Compounds derived from sulfonamide, inhibitors of beta amyloid production; Preparation method; pharmaceutical composition; pharmaceutical kit; and use in the treatment of diseases such as Alzheimer's, amyloid angiopathy, down syndrome, among others.